Caissa Capital Management ltd. - 25 Apr 2023 Form 4 Insider Report for Avalo Therapeutics, Inc. (AVTX)

Role
10%+ Owner
Signature
Cambyz Golestaneh, Title: Director
Issuer symbol
AVTX
Transactions as of
25 Apr 2023
Net transactions value
+$22,423
Form type
4
Filing time
27 Apr 2023, 16:07:38 UTC
Previous filing
24 Apr 2023
Next filing
08 May 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AVTX Common Stock Purchase $16,709 +5,571 +0.43% $3.00* 1,315,771 25 Apr 2023 See Footnote (1) F1, F2
transaction AVTX Common Stock Purchase $1,262 +425 +0.03% $2.97* 1,316,196 26 Apr 2023 See Footnote (1) F1
transaction AVTX Common Stock Purchase $4,452 +1,504 +0.11% $2.96* 1,317,700 27 Apr 2023 See Footnote (1) F1, F3
holding AVTX Common Stock 182,300 25 Apr 2023 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh.
F2 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.97 to $3.05, inclusive.
F3 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.95 to $2.97, inclusive.
F4 These shares are directly owned by Mr. Golestaneh in his personal capacity.